NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
1.970
-0.030 (-1.50%)
At close: Jul 10, 2026, 4:00 PM EDT
1.980
+0.010 (0.51%)
After-hours: Jul 10, 2026, 6:12 PM EDT
NextCure Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
7.12M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bolt Biotherapeutics | 6.50M |
| Can-Fite BioPharma | 405.00K |
| AIM ImmunoTech | 94.00K |
| Aspire Biopharma Holdings | 34.56K |
| Pulmatrix | 3.00K |
| Ernexa Therapeutics | 1,000.00 |
NXTC News
- 23 days ago - NextCure Transcript: AGM 2026 - Transcripts
- 5 weeks ago - NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers - GlobeNewsWire
- 5 weeks ago - NextCure Transcript: KOL event - Transcripts
- 5 weeks ago - NextCure Press release: KOL event - Filings
- 5 weeks ago - NextCure Slides: KOL event - Filings
- 5 weeks ago - NextCure share weakness overdone, says Lucid Capital - TheFly
- 5 weeks ago - NextCure presents Phase 1 data for SIM0505 in gynecologic cancers - TheFly
- 5 weeks ago - NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 - GlobeNewsWire